Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation.
Status: Enrolling
Updated:  1/11/2016
Novartis Investigative Site
mi
from
Sydney,
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation.
Status: Enrolling
Updated: 1/11/2016
Novartis Investigative Site
mi
from
Sydney,
Click here to add this to my saved trials
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Burbank, CA
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Los Angeles, CA
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Palm Springs, CA
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Palm Springs, CA
Click here to add this to my saved trials
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Boca Raton, FL
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Honolulu, HI
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
New York, NY
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated:  1/11/2016
Research Site
mi
from
Fitzroy,
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
Status: Enrolling
Updated: 1/11/2016
Research Site
mi
from
Fitzroy,
Click here to add this to my saved trials
Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer
GeneSearch™ Breast Lymph Node (BLN) Assay for Molecular Testing Protocol
Status: Enrolling
Updated:  1/11/2016
Indiana University Hospital
mi
from
Indianapolis, IN
Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer
GeneSearch™ Breast Lymph Node (BLN) Assay for Molecular Testing Protocol
Status: Enrolling
Updated: 1/11/2016
Indiana University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated:  1/11/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated: 1/11/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated:  1/11/2016
Georgetown University Medical Center
mi
from
Washington,
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated: 1/11/2016
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated:  1/11/2016
Morton Plant Hospital
mi
from
Clearwater, FL
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated: 1/11/2016
Morton Plant Hospital
mi
from
Clearwater, FL
Click here to add this to my saved trials
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated:  1/11/2016
St. Anthony's Hospital
mi
from
St. Petersburg, FL
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated: 1/11/2016
St. Anthony's Hospital
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated:  1/11/2016
Georgia Esoteric and Molecular Labs, LLC
mi
from
Augusta, GA
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated: 1/11/2016
Georgia Esoteric and Molecular Labs, LLC
mi
from
Augusta, GA
Click here to add this to my saved trials
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated:  1/11/2016
Woman's Hospital
mi
from
Flowood, MS
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Status: Enrolling
Updated: 1/11/2016
Woman's Hospital
mi
from
Flowood, MS
Click here to add this to my saved trials
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated:  1/11/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated: 1/11/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated:  1/11/2016
Georgetown University Medical Center
mi
from
Washington,
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated: 1/11/2016
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated:  1/11/2016
Morton Plant Hospital
mi
from
Clearwater, FL
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated: 1/11/2016
Morton Plant Hospital
mi
from
Clearwater, FL
Click here to add this to my saved trials
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated:  1/11/2016
St. Anthony's Hospital
mi
from
St. Petersburg, FL
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated: 1/11/2016
St. Anthony's Hospital
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated:  1/11/2016
Georgia Esoteric and Molecular Labs, LLC
mi
from
Augusta, GA
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated: 1/11/2016
Georgia Esoteric and Molecular Labs, LLC
mi
from
Augusta, GA
Click here to add this to my saved trials
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated:  1/11/2016
Woman's Hospital
mi
from
Flowood, MS
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
Status: Enrolling
Updated: 1/11/2016
Woman's Hospital
mi
from
Flowood, MS
Click here to add this to my saved trials
Koning Breast Computed Tomography Guided Neoadjuvant Treatment Monitoring
Koning Breast CT (KBCT)-Guided Neoadjuvant Treatment of Breast Cancer Monitoring Phase I Trial
Status: Enrolling
Updated:  1/12/2016
University of Rochester Medical Center, Highland Breast Imaging Center
mi
from
Rochester, NY
Koning Breast Computed Tomography Guided Neoadjuvant Treatment Monitoring
Koning Breast CT (KBCT)-Guided Neoadjuvant Treatment of Breast Cancer Monitoring Phase I Trial
Status: Enrolling
Updated: 1/12/2016
University of Rochester Medical Center, Highland Breast Imaging Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Enhancing Exercise in Breast Cancer Survivors
Enhancing Exercise in Breast Cancer Survivors
Status: Enrolling
Updated:  1/12/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Enhancing Exercise in Breast Cancer Survivors
Enhancing Exercise in Breast Cancer Survivors
Status: Enrolling
Updated: 1/12/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Yoga for Aromatase Inhibitor-associated Joint Pain
Evaluating Yoga for Aromatase Inhibitor-associated Joint Pain in Women With Breast Cancer: A Pilot Study
Status: Enrolling
Updated:  1/12/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Yoga for Aromatase Inhibitor-associated Joint Pain
Evaluating Yoga for Aromatase Inhibitor-associated Joint Pain in Women With Breast Cancer: A Pilot Study
Status: Enrolling
Updated: 1/12/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma
Status: Enrolling
Updated:  1/12/2016
Emory University Hospital Midtown
mi
from
Atlanta, GA
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma
Status: Enrolling
Updated: 1/12/2016
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma
Status: Enrolling
Updated:  1/12/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma
Status: Enrolling
Updated: 1/12/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Identification and Semi -Quantification of ER/PR Proteins Expression
Identification and Semi -Quantification of ER/PR Proteins Expression Status in Formalin Fixed, Paraffin-embedded Normal and Neoplastic Tissue
Status: Enrolling
Updated:  1/12/2016
Scott & White Hospital
mi
from
Temple, TX
Identification and Semi -Quantification of ER/PR Proteins Expression
Identification and Semi -Quantification of ER/PR Proteins Expression Status in Formalin Fixed, Paraffin-embedded Normal and Neoplastic Tissue
Status: Enrolling
Updated: 1/12/2016
Scott & White Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2) -Overexpressing Inflammatory Breast Cancer
An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
Status: Enrolling
Updated:  1/13/2016
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2) -Overexpressing Inflammatory Breast Cancer
An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
Status: Enrolling
Updated: 1/13/2016
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2) -Overexpressing Inflammatory Breast Cancer
An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
Status: Enrolling
Updated:  1/13/2016
1245.25.10053 Boehringer Ingelheim Investigational Site
mi
from
Durham, NC
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2) -Overexpressing Inflammatory Breast Cancer
An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
Status: Enrolling
Updated: 1/13/2016
1245.25.10053 Boehringer Ingelheim Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2) -Overexpressing Inflammatory Breast Cancer
An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
Status: Enrolling
Updated:  1/13/2016
1200.89.61002 Boehringer Ingelheim Investigational Site
mi
from
East Bentleigh,
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2) -Overexpressing Inflammatory Breast Cancer
An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
Status: Enrolling
Updated: 1/13/2016
1200.89.61002 Boehringer Ingelheim Investigational Site
mi
from
East Bentleigh,
Click here to add this to my saved trials
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
A Phase 1 Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  1/14/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
A Phase 1 Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 1/14/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/14/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/14/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
Diet, Exercise and Estrogen Metabolites Study (DEEM)
Status: Enrolling
Updated:  1/15/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
Diet, Exercise and Estrogen Metabolites Study (DEEM)
Status: Enrolling
Updated: 1/15/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
mi
from
Birmingham, AL
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Washington Cancer Institute at Washington Hospital Center
mi
from
Washington,
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Washington Cancer Institute at Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Baylor University Medical Center - Houston
mi
from
Houston, TX
Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Baylor University Medical Center - Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
Phase I Radiosensitization Study of GW572016 With Biologic Correlates in Locoregionally Recurrent Breast Cancer
Status: Enrolling
Updated:  1/17/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
Phase I Radiosensitization Study of GW572016 With Biologic Correlates in Locoregionally Recurrent Breast Cancer
Status: Enrolling
Updated: 1/17/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated:  1/18/2016
Los Angeles County Hospital
mi
from
Los Angeles, CA
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated: 1/18/2016
Los Angeles County Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated:  1/18/2016
University of Southern California - Norris
mi
from
Los Angeles, CA
Assessing the Patient Experience in Cancer Care
Assessing the Patient Experience in Cancer Care: An Observational Communication Study
Status: Enrolling
Updated: 1/18/2016
University of Southern California - Norris
mi
from
Los Angeles, CA
Click here to add this to my saved trials